A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions

Biomaterials
Yi MaAn Hong

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuroendocrine factor that activates both the receptor VPAC1 and VPAC2. Although PACAP possesses insulinotropic activity, its therapeutic application is limited by the extremely short acting half-life and the stimulatory effects on glucagon production via a VPAC1-dependent mechanism. Here we have generated a recombinant PACAP-derived peptide (named as MHDBAY) comprising a 7-mer albumin-binding peptide identified by phage display screening (WQRPSSW), a cleavage peptide for Factor Xa (FXa) and dipeptidyl peptidase IV (DPP IV), and a 31-amino acid PACAP-derived peptide (DBAY) that can specifically bind to the VPAC2 receptor. MHDBAY binds to albumin both in vitro and in animals, thereby leading to an orderly slow release of the active peptide DBAY via the protease cleavage. In db/db mice and New Zealand rabbits, the circulating half-life of MHDBAY is approximately 12.2 h, which is 146-fold longer than DBAY (∼5 min). A single injection of MHDBAY into db/db diabetic mice markedly increases insulin secretion, thereby leading to sustained alleviation of hyperglycemia. The potency and duration of MHDBAY in increasing insulin secretion and decreasing blood glucose levels is ...Continue Reading

References

Jan 5, 2002·Proceedings of the National Academy of Sciences of the United States of America·Carol HamelinkLee E Eiden
Jul 18, 2002·The Journal of Biological Chemistry·Mark S DennisLisa A Damico
Dec 28, 2002·Chemical Senses·Andrew Kurt Thaw, Thomas J Quinn
Jan 18, 2003·Receptors & Channels·M LaburtheJ C Marie
May 24, 2003·Trends in Molecular Medicine·David Pozo
Jul 23, 2004·Expert Opinion on Biological Therapy·Rajendra PawarAbraham J Domb
Sep 10, 2005·Nature Biotechnology·Philipp Holliger, Peter J Hudson
Sep 29, 2005·Diabetes Research and Clinical Practice·Sora LudwigGarry X Shen
Feb 21, 2006·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·D K Arulmozhi, B Portha
Aug 5, 2006·Annals of the New York Academy of Sciences·Akira ArimuraVecihi Batuman
Aug 5, 2006·Annals of the New York Academy of Sciences·R P GomarizC Martinez
Oct 20, 2006·Current Opinion in Biotechnology·Aaron K SatoClive R Wood
Nov 18, 2006·The Journal of Pharmacology and Experimental Therapeutics·Clark Q PanJames P Whelan
Mar 10, 2007·The Journal of Biological Chemistry·Dafne MüllerRoland E Kontermann
Apr 26, 2007·Current Drug Delivery·Dhirendra Kumar MalikJaved Ali
May 1, 2008·Journal of Pharmacological Sciences·Shuhei TomimotoAkemichi Baba
Jul 8, 2008·Current Opinion in Pharmacology·Duncan Patrick McGregor
Sep 9, 2008·Trends in Molecular Medicine·Keren BorensztajnC Arnold Spek
Aug 21, 2009·Journal of Veterinary Emergency and Critical Care·Louis G Licari, Jan P Kovacic
Nov 3, 2009·Diabetes, Obesity & Metabolism·T Vilsbøll
Sep 11, 2010·Nature Biotechnology·Gary Walsh
May 23, 2012·Clinical Therapeutics·Vanita R ArodaByron J Hoogwerf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.